LCC in Italian: Virtual Tumor Board - Resectable NSCLC

In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.

LCC in Korean: Lung Cancer Updates & Future Directions by IASLC

Global Advances and Persistent Disparities in Lung Cancer Treatment by IASLC

Dr. Bryant Lin Teaching My Cancer by IASLC

AACR 2025 Highlights by IASLC

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Mihaela Aldea about the key information about RET-positive NSCLC, from diagnostic challenges to treatment selection. Join us in this lively discussion.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion live from the Texas Lung Cancer Conference with Dr. Eric Singhi and Dr. Misty Shields about patient education and communication. Tune in to hear the top things to discuss during your first oncology visit, including conflict and miscommunication resolution.

Guest: Dr. Corey Langer is the Director of Thoracic Oncology and Professor of Medicine at the Hospital of the University of Pennsylvania

LCC in Korean: 2024 Lung Cancer Updates by IASLC

LCC in Italian: Virtual Tumor Board - Resectable NSCLC by IASLC